PTO/SB/68 (11-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED
MAR 0 1 2001
File Information Unit

In re Application of	
Ullrich	
Application Number	**Filed**
07/975,750	11/13/92
Group Art Unit	**Examiner**

Paper No. #15

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

___ (A) referred to in United States Patent Number 6,177,401 B1, column _____,

___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____,

___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

_____

_____

_____

Violetta Bourdette — 02/01/01

Signature — Date

Violetta Bourdette

Typed or printed name

FOR PTO USE ONLY

Approved by: _____ (initials)

Unit: _____

US006177401B1

(12) **United States Patent**
Ullrich et al.

(10) **Patent No.: US 6,177,401 B1**
(45) **Date of Patent: Jan. 23, 2001**

(54) **USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS**

(75) Inventors: **Axel Ullrich**, München; **Werner Risau**, Grafelfing; **Birgit Millauer**, München, all of (DE)

(73) Assignee: **Max-Planck-Gesellschaft zur Forderung der Wissenschaften**, Martinsried (DE)

(*) Notice: Under 35 U.S.C. 154(b), the term of this patent shall be extended for 0 days.

(21) Appl. No.: **08/193,829**

(22) Filed: **Feb. 9, 1994**

Related U.S. Application Data

(63) Continuation-in-part of application No. 08/038,596, filed on Mar. 26, 1993, now abandoned, which is a continuation-in-part of application No. 07/975,750, filed on Nov. 13, 1992, now abandoned.

(51) **Int. Cl.**[7] **A61K 31/00**

(52) **U.S. Cl.** **514/1**; 435/7.2; 436/501; 530/350; 530/399

(58) **Field of Search** 536/23.5; 435/69.1, 435/172.1, 240.2, 252.3, 320.1, 325, 361, 7.2; 424/93.2; 514/44, 1; 935/32, 57, 70, 71; 436/501; 530/399, 350

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,185,438	2/1993	Lemishka .
5,712,395	1/1998	App et al. .
5,763,441	6/1998	App et al. .
5,766,860	6/1998	Terman et al. .
5,792,771	8/1998	App et al. .
5,792,783	8/1998	Tang et al. .
5,869,742	2/1999	Köster et al. .

FOREIGN PATENT DOCUMENTS

WO 92/03459	3/1992	(WO) .
WO 92/14748	9/1992	(WO) .
WO 92/17486	10/1992	(WO) .
WO 94/10202	5/1994	(WO) .
WO 95/21868	8/1995	(WO) .
WO 96/20403	7/1996	(WO) .

OTHER PUBLICATIONS

S.H. Orkin Et Al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", Dec. 7, 1995.*

H. Ueno et al.., Science 252:844–848, May 10, 1991.*

H. Ueno et al.., J. Biol. Chem. 267(3):1470–1476, Jan. 25, 1992.*

L.A. Tartaglia et al., J. Biol. Chem. 267(7), 4304–4307, Mar. 5, 1992.*

Risau et al., 1988, "Changes in the Vascular Extracellular Matrix During Embryonic Vasculogenesis and Angiogenesis," *Development Biology 125*:441–450.

Ferrara et al., 1989, "Pituitary Follicular Cells Secrete a Novel Heparin–Binding Growth Factor Specific for Vascular Endothelial Cells," *Biochem. Biophys. Res. Comm. 161*:851–858.

Gospodarowicz et al., 1989, "Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary–Derived Folliculo Stellate Cells," *Proc. Natl. Acad. Sci. USA 86*:7311–7315.

Leung et al., 1989, "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," *Science 246*:1306–1309.

Conn et al., 1990, "Purification of a Glycoprotein Vascular Endothelial Cell Mitogen From a Rat Glioma–derived Cell Line," *Proc. Natl. Acad. Sci. USA 87*:1323–1327.

Ullrich et al., 1990, "Signal transduction by receptors with tyrosine kinase activity", *Cell 61*:203–212.

Ferrara et al., 1991, "The Vascular Endothelial Growth Factor Family of Polypeptides," *J. Cell Biochem. 47*:211–218.

Kashles et al., 1991, "A Dominant Negative Mutation Suppresses the Function of Normal Epidermal Growth Factor Receptors by Heterodimerization," *Mol. Cell. Biol. 11*:1454–1463.

Klagsburn et al., 1991, "Regulators of Angiogenesis" *Annu. Rev. Physiol. 53*:217–39.

Maglione et al., 1991, "Isolation of Human Placental cDNA Coding For a Protein Related to the Vascular Permeability Factor," *Proc. Natl. Acad. Sci. USA 88*:9267–9271.

Matthews et al., 1991, "A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primative Hematopoietic Cells and Exhibiting Close Genetic Linkage to c–kit," *Proc. Natl. Acad. Sci. USA 88*:9026–9030.

Mitchell et al., 1991, "Recombinant Expression and Characterization of the 121 Amino Acid Form of Vascular Endothelial Growth Factor (VEGF)," *J. Cell. Biochem., Keystone Symposia on Molecular and Cellular Biology*, Supplement 15C, Excerpt G207.

(List continued on next page.)

Primary Examiner—Lorraine Spector
(74) *Attorney, Agent, or Firm*—Foley & Lardner

(57) **ABSTRACT**

The present invention relates to the use of proteins, peptides and organic molecules capable of modulating Flk-1 receptor signal transduction in order to inhibit or promote angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described.

The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.

16 Claims, 25 Drawing Sheets